Dragon Pharma Ovagen 20 MG

IDENTITYCompoundOvagen
ActiveOvagen Peptide
Strength20 mg
FormLyophilized Powder
ClassKhavinson Peptide / Bioregulator

PEPTIDE PROFILECategoryShort Peptide Bioregulator
OriginOrgan-Specific Peptide Complex
FunctionCellular Regulation Support
Research AreaPeptide Biology & Tissue Regulation
FormFreeze-Dried Vial

PHARMACOLOGYMechanismPeptide Signaling Regulation
AdministrationSubcutaneous Injection (SC)
ActivityBioregulatory Peptide Profile
Hormonal EffectNo Direct Androgenic Activity
PCTNot Required

STORAGE & PACKAGEBrandDragon Pharma
Package2 ml Vial x 20 mg
Storage2–8°C Recommended
ProtectionProtect From Light
FormLyophilized Powder

ADMINISTRATION PROFILEUsageSubcutaneous Administration
DilutionReconstitution Required
Injection SiteSubcutaneous Tissue
FrequencyDaily Administration
TimingMorning / Evening Protocol

DOSING INFORMATIONStandard Dose10–20 mg/day
Weekly Amount70–140 mg/week
AdministrationDaily (7 days/week)
Typical Duration10–30 days
ProtocolShort Peptide Course

BODYBUILDING USAGE Primary UseRecovery Support
Training PhaseIntensive Training Periods
Daily Dose10–20 mg/day
Course Length2–4 Weeks
CombinationRecovery-Focused Protocols

USAGE PROFILEStartDay 1 Protocol Initiation
Duration10–30 Days
Peak ActivityDuring Active Peptide Exposure
RecoveryPost-Training Support
MaintenanceStructured Cycles

MECHANISM OF ACTIONTargetCellular Regulatory Pathways
SignalPeptide-Mediated Regulation
FunctionTissue-Specific Communication
RecoveryCellular Support Processes
HormonesNo Direct Hormonal Suppression

PHARMACOKINETICSReleasePeptide Absorption Profile
MetabolismPeptide Degradation Pathways
DurationShort Biological Activity
ClearanceProteolytic Metabolism
ExposureRepeated Daily Administration

SAFETY PROFILEHormonal SuppressionNot Expected
Liver ToxicityNo Known Direct Hepatotoxic Effect
CardiovascularMonitoring Recommended
Immune ResponsePossible Peptide Sensitivity
MonitoringHealth Assessment Recommended

CONTRAINDICATIONSPregnancyNot Recommended
AllergyAvoid If Sensitive
Medical ConditionsProfessional Evaluation
Storage DamageDo Not Use
Reconstituted ProductFollow Storage Guidelines

RECOVERY & DISCONTINUATION PCTNot Required
Stopping TimeAfter Completed Course
RecoveryNatural Peptide Clearance
Hormonal AxisNo HPTA Suppression
Break PeriodStructured Intervals

COMPATIBILITYRecovery StackSleep & Nutrition Support
TrainingHigh Volume Programs
PerformanceRecovery Focused Compounds
SupportProtein & Micronutrients
ApproachNon-Hormonal Protocol

PROTOCOL FEATURESWeek 1Initial Peptide Exposure
Week 2Continued Cellular Support
Week 3-4Completion Phase
Daily Use10-20 mg/day
Total Course70-560 mg Depending Duration

RECONSTITUTION INFORMATIONFormLyophilized Powder
Vial Size20 mg
DilutionRequires Sterile Solution
HandlingAseptic Technique
StorageCold Temperature Protection

CHEMICAL PROFILECompoundOvagen Peptide
FormulaPeptide Complex
Molecular WeightNot Publicly Established
CASNot Established
ClassBioregulatory Peptide

OVERVIEW

Dragon Pharma Ovagen 20 MG is a lyophilized peptide bioregulator classified within the Khavinson peptide research category. Ovagen is designed around short peptide signaling concepts associated with cellular communication and tissue-specific regulation.

BENEFITS

Non-androgenic peptide profile
Recovery-focused application
Cellular regulation support
Suitable for structured peptide protocols
No direct HPTA suppression
Compatible with training recovery strategies
Lyophilized pharmaceutical presentation

POTENTIAL RISKS

Limited large-scale clinical research
Possible injection-site reactions
Individual peptide sensitivity
Storage-related stability issues
Need for sterile administration
Limited human performance data

PERFORMANCE PROFILE

Recovery Support

80%

Cellular Support

75%

Hormonal Impact

15%

Fat Loss Effect

20%

Muscle Building

35%

CONCLUSION

Dragon Pharma Ovagen 20 MG is a lyophilized peptide bioregulator product containing Ovagen, a compound classified within the Khavinson peptide research category. The product is designed for structured peptide protocols focused on cellular signaling, recovery support and physiological regulation.

Unlike anabolic steroids or hormonal compounds, Ovagen does not function through androgen receptor activation and is not associated with direct testosterone suppression or traditional PCT requirements. Its application in bodybuilding communities is primarily centered around recovery strategies, training adaptation and general peptide-based support.

Typical protocols described for Ovagen involve daily administration with doses commonly ranging from 10–20 mg/day over short peptide courses of approximately 10–30 days. Because peptide research continues to develop, responsible use requires attention to product handling, sterile administration and individual health considerations.

In bodybuilding and athletic environments, Ovagen is mainly discussed as a recovery-oriented peptide compound due to its non-androgenic profile and potential role in supporting physiological adaptation during demanding training periods.

WHY CHOOSE DRAGON PHARMA

Dragon Pharma Ovagen 20 MG is manufactured as a pharmaceutical-style peptide presentation using a lyophilized powder format designed to preserve compound stability before preparation.

Professional pharmaceutical packaging format
20 mg lyophilized peptide vial presentation
Designed for structured peptide protocols
Clear product identification and dosage information
Suitable for research-focused peptide applications
Consistent vial format for controlled handling

DISCLAIMER

This content is provided exclusively for educational and informational purposes. It does not constitute medical advice, treatment recommendations or endorsement of non-prescribed pharmaceutical use. Peptide compounds should be evaluated according to applicable medical guidance, scientific evidence and local regulations.